Prolonged Succinylcholine Action During Electroconvulsive Therapy (ECT) After Cytarabine, Vincristine, and Rituximab Chemotherapy
Authors:
- Ethan O. BrysonEBEthan O. Bryson
- Amy S. AloysiAAAmy S. Aloysi
- Andrew M. PerezAPAndrew M. Perez
- Dennis PopeoDPDennis Popeo
- Charles H. KellnerCKCharles H. Kellner
- 1 March 2011
- journal article
- case report
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 27 (1) , e42-e43
Abstract
Succinylcholine is a depolarizing neuromuscular blocker frequently used during electroconvulsive therapy. In most patients, the duration of paralysis is brief, allowing for spontaneous respiration shortly after the therapy. We report a case of delayed return of neuromuscular function after succinylcholine administered during electroconvulsive therapy in a 72-year-old man receiving cytarabine, vincristine, and rituximab chemotherapy for chronic lymphocytic leukemia. We hypothesize that an interaction between succinylcholine and one of the chemotherapeutic agents caused the prolongation of paralysis and believe that this is the first reported case of prolonged duration of succinylcholine following this regimen of chemotherapy. Despite this unexpected prolonged neuromuscular blockade, the patient could be treated uneventfully, with attention paid to his respiratory support and with subsequent succinylcholine dose titration to effect.Keywords
This publication has 3 references indexed in Scilit:
- Acquired pseudocholinesterase deficiency after high-dose cyclophosphamideBone Marrow Transplantation, 1999
- Correlation of Succinylcholine Duration of Action with Plasma Cholinesterase Activity in Subjects with the Genotypically Normal EnzymeAnesthesiology, 1980
- ECOTHIOPATE IODIDE EYE DROPS AND PROLONGED RESPONSE TO SUXAMETHONIUMBritish Journal of Anaesthesia, 1966